Accueil   Diary - News   All news ElsaLys Biotech and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

ElsaLys Biotech and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

  • ELB021 is a proprietary first-in-class monoclonal antibody targeting CD160, a multifunctional target expressed on both immune & leukemia cells.
  • With the support of the EU program Eurostar1, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation immunotherapy which acts both as immune checkpoint inhibitor and cytotoxic antibody.
  • Once validated, ELB021 should enter clinical development in 2020.

 

Lyon, FRANCE, 18 July 2017, ELSALYS BIOTECH, an emerging player in the field of oncology & ophthalmology, announces today that ELB021, its first-in-class monoclonal antibody targeting the cell-surface receptor CD160, has entered into a preclinical collaboration with DKFZ (the “LeukeMab Project”) under a EU-sponsored program Eurostars*.

 

In-licensed by ELSALYS BIOTECH from Inserm Transfert in February 2016, ELB021 is a next-generation immunotherapy antibody combining complementary mechanisms of action that could improve the efficacy/toxicity cancer treatment ratio, notably in B-cell leukemias such as Chronic Lymphoid and Hairy-Cell Leukemias (CLL and HCL). Early studies have already shown that ELB021:

 

  • stimulates innate & adaptive anti-tumor immune response;
  • eliminates selectively cancer cells expressing CD160 (normal B cells doesn’t express CD160 while the receptor is overexpressed in 98 % of CLL and in 100 % of HCL cells).

 

 

 

 

 Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree